“Clinicians want to do what’s best for their patients, for their staff and for practices,” said Dr. Stephen "Fred" Divers, Chairman of the AON Advisory Board and a practicing Medical Oncologist. “They want to make the right decisions at the right time, but they’re often overwhelmed by data which is poorly accessible and manageable, leading to clinical workflow burdens which get in the way of achieving the best outcomes for their patients. They need a technology solution that helps simplify cancer’s complexities and empowers them to do their best. At AON, we partner with physicians and their practices to help them navigate the complex oncologic landscape, improve quality of care and elevate oncology in community settings. VieCure aligns perfectly with that mission.”

AON leadership recognized the need for 21st century clinical decision making tools and turned to VieCure to be their partner. The two entities will work together to codify AON's unique clinical content including but not limited to therapeutic and drug contracts, commercial payer rules and clinical trials.


“We understand that knowledge is the secret to beating cancer,” said Dr. Fred Ashbury, Chief Scientific Officer at VieCure. “That’s why we’re embracing the power of clinical inferencing to do what the human brain cannot, which is to enable clinicians to easily sift through the overwhelming amount of information to find the right answers for every patient, every time. At VieCure we’re about creating simplexity in cancer care, which means we use AI technology to cut through the dense fog of information that holds clinicians back; we help to superpower them to do their best work. By codifying the latest in clinical evidence and financial rules, we can envelop our clinicians with a halo of knowledge in real time which can be easily and quickly interpreted and actioned right at the point of care.”

The multi-year strategic collaboration will not only serve to meet the clinical needs of the AON community today but will ensure the VieCure™ platform evolves over time. Together the parties have committed to:

Joint research and development, creating and deploying new features and technology innovations as the oncology landscape changes.
Advancing access to, and administration of, the latest codified content including national and international evidence, therapy (eg. drug/bio-similar) agreements, and phase I, II, and III clinical trials.
Centralization of precision oncology infrastructure including one-click order entry for next generation tumor sequencing and the return of relevant discrete data to facilitate real-time clinical inferencing of results to help guide treatment selection and management decisions.

Rad Oncology Homepage